AbbVie Inc. (ABBV) Stock Analysis
Healthcare · Drug Manufacturers - General · $433B · $245.10 · scored 2026-08-04
Directional estimate from the GemStox stochastic + volatility models. Not financial advice.
Strategy-class scores
GemStox scores ABBV across 11 independent investment-thesis classes. The meta score is the consensus of the strongest signals.
| Strategy class | Score /100 | What it tests |
|---|---|---|
| GARP | Growth at a Reasonable Price | |
| Mean Reversion | Oversold bounce | |
| Quality Compounder | Wide-moat compounder | |
| CAN SLIM best fit | O'Neil IBD system | |
| Low-Vol Defensive | Low-volatility defensive | |
| Catalyst / Event | Filing + news + earnings catalyst | |
| Dividend Growth | Dividend-growth safety | |
| S-Curve Growth | S-curve lifecycle growth | |
| Piotroski F-Score | Piotroski 9-point F-Score | |
| Operating Leverage | Operating leverage | |
| Net Payout Yield | Net cash payout yield |
Valuation
What the price is paying for — earnings yield, FCF yield, P/B, PEG, and Graham discount.
| PEG (growth-adjusted) | strong · GARP | |
| Price-to-sales / growth | strong · GARP | |
| Forward vs trailing P/E | strong · GARP | |
| Cash-cow yield (Chowder) | weak · Dividend Growth |
Quality
Earnings power and durability — ROE, margins, FCF quality, balance-sheet safety.
| Return on equity | neutral · Quality Compounder | |
| Gross margin | strong · Quality Compounder | |
| Free-cash-flow quality | neutral · Quality Compounder | |
| Debt vs free cash flow | neutral · Quality Compounder | |
| Institutional holding | strong · CAN SLIM | |
| Earnings consistency | strong · CAN SLIM | |
| Balance-sheet safety | weak · Dividend Growth | |
| Piotroski F-Score | 4/9 — deteriorating fundamentals · Piotroski F-Score |
Risk
How it can lose — beta, volatility, drawdowns, downside profile, and financial stability.
| Beta (market sensitivity) | strong · Low-Vol Defensive | |
| Drawdown resilience | weak · Low-Vol Defensive | |
| Volatility control | weak · Low-Vol Defensive | |
| Downside-adjusted return | weak · Low-Vol Defensive | |
| Dividend safety cushion | solid · Low-Vol Defensive |
Growth
Where it's going — revenue and EPS trends, surprises, and new-inflection signals.
| Revenue growth | strong · GARP | |
| Earnings surprise | strong · GARP | |
| Current EPS trend | strong · CAN SLIM | |
| Annual EPS trend | strong · CAN SLIM | |
| New highs / inflection | weak · CAN SLIM | |
| Dividend-growth streak | weak · Dividend Growth | |
| S-curve trajectory | weak · S-Curve Growth | |
| Growth persistence | weak · S-Curve Growth | |
| Scale of growth | strong · S-Curve Growth | |
| Growth divergence | weak · S-Curve Growth |
Momentum & Technicals
Price action — trend, relative strength, RSI, and catalysts.
| RSI (14) | oversold · Mean Reversion | |
| Bollinger %B | weak · Mean Reversion | |
| Distance to 200-day MA | weak · Mean Reversion | |
| Exhaustion | weak · Mean Reversion | |
| Short squeeze | weak · Mean Reversion | |
| Supply / demand | weak · CAN SLIM | |
| Relative strength rating | solid · CAN SLIM | |
| Market breadth | strong · CAN SLIM | |
| Filing catalyst | weak · Catalyst / Event | |
| Earnings proximity | neutral · Catalyst / Event | |
| Price catalyst | solid · Catalyst / Event | |
| Volume catalyst | weak · Catalyst / Event | |
| Yield quality | weak · Dividend Growth | |
| Operating-leverage ratio | weak · Operating Leverage | |
| Net payout value | weak · Net Payout Yield |
How this score is computed
Each of the 14 strategy classes is a pure function of the same market + fundamentals data — no two theses double-count. AbbVie Inc. currently fits the CAN SLIM thesis best, with 4/11 of 11 classes producing a positive read. Read the full scoring methodology, or try the free Stock Score calculator to see the math on any ticker.
See all 14 live signals for ABBV
The public page shows the consensus. The full GemStox signal stack — probability scores, optimal position size, and pre-calculated stop/target levels — is one payment away.
Unlock with the $3 Day Pass →Educational analysis generated from cached market + fundamentals data as of 2026-08-04. Not investment advice. Past performance does not guarantee future results.